Drug Profile
Factor IIa/Xa inhibitor - Bayer Schering Pharma
Latest Information Update: 22 Mar 2010
Price :
$50
*
At a glance
- Originator Bayer Schering Pharma
- Class
- Mechanism of Action Factor Xa inhibitors; Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Acute coronary syndromes
Most Recent Events
- 20 Feb 2008 Phase-I clinical trials in Acute coronary syndromes in Europe (unspecified route)